Tags : VISIBLE 2

Takeda Reports Results of Entyvio (vedolizumab SC) in P-III VISIBLE

Tuba Khan July 22, 2019

Shots: The P-III VISIBLE 2 study involves assessing of Entyvio (108 mg, SC) vs PBO SC as a maintenance therapy in 644 patients with moderately to severely active CD who […]readmore

Tags : VISIBLE 2

Takeda Reports Results of Entyvio (vedolizumab SC) in P-III VISIBLE

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : VISIBLE 2

﻿Takeda Reports Results of Entyvio (vedolizumab SC) in P-III VISIBLE

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company

Takeda Reports Results of Entyvio (vedolizumab SC) in P-III VISIBLE